Prourokinase

Prourokinase is a single-chain protein containing 411 amino acids (261,265,274,275). In clinical uses scu-PA does not bind to fibrin only and its use causes a decreased plasma fibrinogen of 80%. Its half-life in the circulation is 5 min. It is cleared by the fiver. It is used at 40—70 mg over 1 h and heparin is needed simultaneously. Fibrin specificity and thrombolytic efficacy are similar to that of t-PA. 

Middle Cerebral Artery Occlusion and the PROACT Trial The safety and efficacy of lAT in the anterior circulation have been evaluated in two randomized, multicenter, placebo-controlled trials. In the Prolyse in Acute Cerebral Thromboembolism (PROACT) 1 and 11 trials, patients with proximal MCA (Ml or M2 segment) occlusions within 6 hours of symptom onset were treated with recombinant prourokinase (r-pro-UK) or placebo. ... 

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999 282 2003-2011. 

Intra-arterial thrombolytics may improve outcomes in selected patients with acute ischemic stroke due to large-vessel occlusion. Patients in the Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial were given 9 mg prourokinase (r-pro UK)... 

Kallikrein, which activates prourokinase, is inhibited by complement I1 esterase inhibitor (C 1-INH). 

Lijnen H. R., Zamarron C., Blaber M. Activation of plasminogen by prourokinase. I. Mechanism. J Biol Chem 1986 261,1253-8. 

Protoporphyrinogen oxidase (protox), crop resistance to, 73 361-362 Prototype pilot plants, 79 459 Protoveratrine A, 2 105 Prourokinase, 5 175, 178... 

Cl. Cajot, J. F., Schleuning, W. D., Medcalf, R. L., Bamat, J., Tetuz, J., Libermann, L., and Sordat, B., Mouse L-cells expressing human prourokinase-type plasminogen activator Effects on extracellular matrix degradation and invasion. J. Cell. Biol. 109, 915-925 (1989). 

Prourokinase (single-chain urokinase) serine protease kidney cells and also lacks fibrin specificity prourokinase exhibits fibrin specificity. 

Recombinant prourokinase, as the name suggests, is produced by recombinant DNA technology on binding to fibrin it converts to urokinase. The t) is 7 min. 

Recombinant prourokinase and alteplase are termed fibrin-selective, for they bind strongly to fibrin, and are capable of dissolving aging or lysis-resistant thrombi better than nonfibrin-selective agents. These drugs are less likely to produce a coagulation disturbance in the plasma, i.e. they are selective for thrombi. 

Japan pro-urokinase antithrombotic Thrombolyse Tomieze Recombinant human prourokinase, clone pA3/pD2/pFl, glycosylated Thrombosis... 

Since the human urokinase gene has now been cloned and expressed in E. coli, the prourokinase enzyme has been produced by recombinant DNA technology. Here, too, the proenzyme binds to fibrin, where, on hydrolytic action, it may exhibit good clot selectivity. The drug is investigational. 

---